报价延迟最少15分钟:2025/11/04 17:44 EST
盘后时段
|
||||
|
38 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
34.74
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.39/-4.83
|
|
企业价值
1.02B
|
| 资产负债 |
|
每股账面净值
-1.60
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
91.28M
|
|
每股收益
0.53
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/11/04 17:44 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
